Condition P08A

Chronic kidney disease with diabetes

Adults with chronic kidney disease and type 2 diabetes enrolled on a kidney criterion.

16 randomized trials; 12 fitted analyses across 15 outcomes.

All outcomes

Each outcome is analyzed per time window and estimand, with doses kept apart (each dose) and pooled (each medicine). Analyses with too few connected trials are shown as descriptive.

eGFR total slopeprimary

O51

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up from week 52	Not stated by the trials	Doses of a drug pooled	1	2	Descriptive only
longest follow-up from week 52	Not stated by the trials	Each dose separately	1	3	Descriptive only
longest follow-up from week 52	Hypothetical (as if everyone stayed on treatment)	Each dose separately	1	2	Descriptive only
longest follow-up from week 52	Hypothetical (as if everyone stayed on treatment)	Doses of a drug pooled	1	2	Descriptive only

SF-36 physical component summary change

O24A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
weeks 20 to 130 (target week 52)	Not stated by the trials	Doses of a drug pooled	1	2	Descriptive only
weeks 20 to 130 (target week 52)	Not stated by the trials	Each dose separately	1	2	Descriptive only

Serious adverse events

O25

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately (part 2)	6	8	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled (part 2)	6	7	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled (part 4)	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled (part 3)	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 3)	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 4)	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Discontinuation due to adverse events

O26

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled (part 2)	4	5	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately (part 2)	4	6	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled (part 3)	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled (part 4)	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 3)	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 4)	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only

Nausea

O27A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled (part 2)	7	8	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately (part 2)	6	8	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 3)	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 4)	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled (part 3)	1	2	Descriptive only

Vomiting

O27B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled (part 2)	5	6	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately (part 2)	5	7	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled (part 3)	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 3)	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Diarrhea

O27C

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately (part 2)	5	7	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled (part 2)	5	6	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled (part 3)	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 3)	1	2	Descriptive only

Constipation

O27D

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately (part 2)	3	4	Network meta-analysis
longest follow-up	Recorded harms	Doses of a drug pooled (part 2)	3	4	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 3)	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled (part 3)	1	2	Descriptive only

Discontinuation due to gastrointestinal adverse events

O27E

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only

Acute pancreatitis

O29

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Medullary thyroid carcinoma

O32A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 2)	1	3	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled (part 2)	1	2	Descriptive only

Thyroid cancer (any)

O32B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 2)	1	3	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled (part 2)	1	2	Descriptive only

Death by suicide

O35B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only

Any cancer

O39

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only

Acute kidney injury

O121

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only